5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial

✍ Scribed by I. Lang; M. Inbar; G. Steger; R. Greil; Z. Zvirbule; S. Beslija; Z. Kahán; V. Taskova; B. Kaufmann; C.C. Zielinski

• Book ID: 119600708
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 68 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(09)70950-4